In a victory for the pharmaceutical industry, the U.S. Supreme Court limited the right for people from anywhere in the country to file product-liability lawsuits against drug makers in California and several other states where courts are seen as more hospitable to consumers.
The ruling came in response to a debate over jurisdiction, which can be used to determine where a lawsuit may be filed. Last year, the California Supreme Court clarified the extent to which Bristol-Myers Squibb needed to have a presence in California in order to be sued by hundreds of people from Texas, Ohio, and 33 other states, who claim they were harmed by its Plavix blood thinner.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
